In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016

Thrombosis Research

Volumn 93, Issue 1, 1999, Pages 43-50

  Wallace, John L ^a   Muscara, Marcelo N ^a   McKnight, Webb ^a   Dicay, Michael ^a   Del Soldato, Piero ^b   Cirino, Giuseppe ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b NicOx SA   (France)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Nitric oxide; Platelet; Thrombosis; Thromboxane; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID 4 NITROXYBUTYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; NITRATE; NITRIC OXIDE; NITRITE; NITROPRUSSIDE SODIUM; THROMBOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STOMACH MUCOSA LESION; STOMACH ULCER; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; ULCEROGENESIS;

ANIMALS; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; MALE; NITRIC OXIDE; NITROPRUSSIDE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; THROMBOXANES;

EID: 0032951722     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00134-0     Document Type: Article

References (24)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 330:1994;1287-1294.
2. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 321:1989;129-135.
3. The RISC Group Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 336:1990;827-830.
4. The SALT Collaborative Group Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 338:1991;1345-1349.
5. Antiplatelet Trialist's Collaboration Collaborative overview of randomized trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Br Med J. 308:1994;81-106.
6. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA. 72:1975;3073-3076.
7. 2 production in healthy subjects. Thromb Res. 17:1980;317-327.
8. Gambino M.C., Passaghe S., Chem Z.M., Bucchi F., Gori G., Latini R., De Gaetano G., Cerletti C. Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyclooxygenase activity is reduced by portocaval shunt in rats. J Pharmacol Exp Ther. 245:1988;287-290.
9. Lee M., Cryer B., Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med. 120:1994;184-189.
10. Meade T.W., Roderick P.J., Brennan P.J., Wilkes H.C., Kelleher C.C. Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost. 68:1992;1-6.
11. Cryer B., Luk G., Feldman M. Effects of very low doses of aspirin (ASA) on gastric, duodenal and rectal prostaglandins (PGs) & mucosal injury. Gastroenterology. 108:1995;A77.
12. Kurata J.H., Abbey D.E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalization. J Clin Gastroenterol. 12:1990;260-266.
13. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 107:1994;173-179.
14. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol. 257:1994;249-255.
15. Davies N.M., Roseth A.G., Appleyard C.B., McKnight W., Del Soldato P., Calignano A., Cirino G., Wallace J.L. NO-naproxen vs. naproxen. ulcerogenic, analgesic and anti-inflammatory effects Aliment Pharm Ther. 11:1997;69-79.
16. Wallace J.L., McKnight W., Del Soldato P., Baydoun A.R., Cirino G. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest. 96:1995;2711-2718.
17. Wallace J.L., McKnight W., Wilson T.L., Cirino G., Del Soldato P., Davies N.M. Nitric oxide-releasing aspirin derivative (NCX 4016). A gastric-sparing anti-thrombotic drug Gastroenterology. 112:1997;A325.
18. 2 production. Thromb Hemostasis. 76:1996;791-798.
19. Paris J., Fournau P., Granero M., Viens C. Antithrombotic effect of very low doses of acetylsalicylic acid in rats. Thromb Res. 29:1983;313-321.
20. Muscará M.N., De Nucci G. Simultaneous determination of nitrite and nitrate anions in plasma, urine and cell culture supernatants by high-performance liquid chromatography with post-column reactions. J Chromatogr B Biomed Appl. 686:1996;157-164.
21. Wallace J.L., McKnight W., Wilson T.L., Del Soldato P., Cirino G. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative. Role of neutrophils Am J Physiol. 273:1997;G1246-G1251.
22. 2-selective and NO-releasing NSAIDs on mucosal ulcerogenic and healing responses in rat stomachs. Gastroenterology. 112:1997;A317.
23. Reyers I., Mussoni L., Donati M.B., de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res. 18:1980;669-674.
24. Ukawa H., Tanaka A., Yamamoto H., Nishijima M., Takeuchi K. Effects of NO-releasing aspirin on functional and mucosal ulcerogenic responses in the rat stomach. Comparison with aspirin Gastroentereology. 114:1998;A314-A315.